StockData
Zevra Therapeutics, Inc. logo

Zevra Therapeutics, Inc. (ZVRA) stock

ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)

Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –

Zevra Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Zevra Therapeutics's EV/EBITDA was 5.7× on Nov 11, 2026, against 22.4× a year earlier.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20265.7×+0.2
2022Apr 29, 20225.5×−17.6
2021Dec 31, 202123.1×–

More Zevra Therapeutics figures

See a number that looks wrong?